<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480009</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17090292</org_study_id>
    <nct_id>NCT03480009</nct_id>
  </id_info>
  <brief_title>Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion</brief_title>
  <acronym>DexMab</acronym>
  <official_title>Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Study Sponsor-Investigator</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates dextromethorphan as a non-opioid adjunctive medication for pain control
      during medication abortion. This is double-blinded, four-arm randomized controlled trial
      enrolling 156 women over a period of 9-12 months: Receiving narcotics+dextromethorphan,
      narcotics and placebo (microcrystalline cellulose), no narcotics and dextromethorphan and no
      narcotics and placebo (microcrystalline cellulose).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Medication abortion using mifepristone and misoprostol is common, accounting for nearly
      one-third of abortions in the United States in 2014. Although women generally tolerate
      medical abortion well, pain and bleeding are common and expected side effects. Up to a
      quarter of women rate their pain as severe during their procedure. Pain management for
      medical abortion is challenging given that the most acute pain occurs at home rather than
      under the supervision of medical professionals. Currently there is insufficient evidence to
      recommend an optimal regimen for pain control in medication abortion and there are concerns
      surrounding narcotic prescribing and the opiate abuse epidemic. This is a four-arm,
      prospective, double-blind, randomized controlled trial comparing dextromethorphan
      administration in conjunction with the current standard regimen (NSAIDs and narcotic
      medication by request- commonly oxycodone or codeine) to the standard regimen alone. Pain
      will be evaluated by analgesia usage and self-reported pain scores. Investigators will also
      investigate factors influencing pain and subjective components of the patient narrative.
      Ideally, a non-opioid adjunct to NSAIDs or narcotics could be used to control pain and
      significantly curtail or avoid opioid use. Investigators seek to test the efficacy and safety
      of dextromethorphan as a non-narcotic analgesic for medication abortion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Worst pain measurement via Numeric Rating Scale (NRS-11)</measure>
    <time_frame>Over 24 hours starting from misoprostol administration</time_frame>
    <description>Self-reported pain measurement via text-messaging system during first 24 hours after misoprostol administration. &quot;0&quot; is no pain at all to &quot;10&quot; is worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pain scores via Numeric Rating Scale (NRS-11)</measure>
    <time_frame>Over a period of 3-5 days from misoprostol administration</time_frame>
    <description>Linear mixed effects models will be used to assess the impact of the intervention on mean pain score and to evaluate whether any baseline demographic or clinical variables are associated with pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Satisfaction with Pain Control via 4-pt Likert Scale</measure>
    <time_frame>24 hours after misoprostol administration</time_frame>
    <description>Overall satisfaction with pain control, &quot;4&quot; being - &quot;Very good&quot; and &quot;1&quot; being &quot;Very bad&quot;</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>Dextromethorphan and narcotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and narcotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan without narcotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and receives active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo without narcotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan Hydrobromide</intervention_name>
    <description>Dextromethorphan capsule</description>
    <arm_group_label>Dextromethorphan and narcotic</arm_group_label>
    <arm_group_label>Dextromethorphan without narcotic</arm_group_label>
    <other_name>Robitussin, Delsym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avicel PH101 (Microcrystalline Cellulose NF) for Compounding</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo and narcotic</arm_group_label>
    <arm_group_label>Placebo without narcotic</arm_group_label>
    <other_name>Avicel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.</description>
    <arm_group_label>Dextromethorphan and narcotic</arm_group_label>
    <arm_group_label>Placebo and narcotic</arm_group_label>
    <other_name>Tylox, Percodan, OxyContin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 and over

          -  Willing to give voluntary consent

          -  English-speaking

          -  Eligible for medication abortion per Planned Parenthood of Western Pennsylvania
             protocol

          -  Self-reported reliable cellular phone access for the duration of study participation

          -  Able to receive and reply to a &quot;test&quot; text at time of consent

          -  Willing to comply with the study protocol

        Exclusion Criteria:

          -  Use of selective serotonin reuptake inhibitors or monoamine oxidase inhibitors due to
             risk of Serotonin Syndrome

          -  Allergy to any component of the medication abortion regimen or study drug

          -  Has any other condition that, in the opinion of the investigator, would preclude
             informed consent, make study participation unsafe, complicate the interpretation of
             the study outcome data, or otherwise interfere with achieving the study objectives

          -  Anticipated use of dextromethorphan during study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must be pregnant to participate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Sponsor-Investigator, MD</last_name>
    <phone>412 641 3710</phone>
    <email>friedgp@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dionne Best</last_name>
    <phone>412-641-5496</phone>
    <email>bestdm@mail.magee.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Penney G. Treatment of pain during medical abortion. Contraception. 2006 Jul;74(1):45-7. Epub 2006 May 6. Review.</citation>
    <PMID>16781260</PMID>
  </reference>
  <reference>
    <citation>Weinbroum AA, Rudick V, Paret G, Ben-Abraham R. The role of dextromethorphan in pain control. Can J Anaesth. 2000 Jun;47(6):585-96. Review.</citation>
    <PMID>10875724</PMID>
  </reference>
  <reference>
    <citation>Ilkjaer S, Nielsen PA, Bach LF, Wernberg M, Dahl JB. The effect of dextromethorphan, alone or in combination with ibuprofen, on postoperative pain after minor gynaecological surgery. Acta Anaesthesiol Scand. 2000 Aug;44(7):873-7.</citation>
    <PMID>10939702</PMID>
  </reference>
  <reference>
    <citation>Christie A, Dagfinrud H, Dale Ã˜, Schulz T, Hagen KB. Collection of patient-reported outcomes;--text messages on mobile phones provide valid scores and high response rates. BMC Med Res Methodol. 2014 Apr 16;14:52. doi: 10.1186/1471-2288-14-52.</citation>
    <PMID>24735061</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014 Mar;123(3):676-92. doi: 10.1097/01.AOG.0000444454.67279.7d.</citation>
    <PMID>24553166</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Study Sponsor-Investigator</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>medication abortion</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>pain control</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Narcotics</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Analgesics, Non-Narcotic</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

